ÃâÒßѧÊÔÌâ
FVNTE+LW Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
I_#
5gq 1. Fas(CD95)/FasL
L5UZ@R, 2. common chain of cytokine receptor
7r:&%?2:g 3 . TCR/CD3 complex
"+2Cs 4. negaive selection of thymocytes
6RIbsy 5. artificial active immune
ElTB{C>u 6. anti-idiotypic
f>xi (0 7. IgSF
zT}vaU6 8. Integrin
Slo^tqbG 9. chemokine
3ouy-SQ 10. B7/CD28
^?]-Q*w3Qs ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
vx7=I\1 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
iM7^ 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
T_s09Wl 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
Mb"y{Fox 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
{m3#1iV9
i@D4bd9lR 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
,j{tGj_ µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
;:oXe*d Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
hMz)l\0
1. B7/CD28
K2Ro0 2. Th1 subset
Uu*iL< ` 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
xR$T/] / 4. antibody affinity maturation
9D
`K#3} 5. AP-1
wjH1Ombt 6. single chain variable fragment£¨ScFv£©
`#W+pO 7. NK cell receptor
h|PC?@jp 8. Zinkernagel-Doherty phenomenon
w\D
!e 9. Ig fold
NNr6~m)3v 10. CD40/CD40L
}=\?]9
` ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
U8N X%*oW 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
- >?tB1}^ 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
S[7^#O.) 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
cK\
u Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
=NY55t
. 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
#Ff8_xhP 2 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
opm_
|0 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
{Ak
4G L Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
}@t"B9D £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
+ansN~3 Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
uY>M3h#qx 1.Co-stimulators (or co-stimulating molecules)
N>*+Wg$Ne 2.NK-kB
&)+H''JY 3.Immunoglobulin superfamily
h/{1(c} 4.antigen-presenting cell (APC)
Ng !d6] 5.death domain
E X'PRNB, 6.CCR and CXCR
.1;UEb|T 7.Lectin (or mitogen)
=z"+)N 8.Clusters of differentiation, CD)
8 I_ 9.B7 family
9`N5$;NzY 10.Cytotoxic T lymphocyte, CTL)
&*7KQd 11.IL-15 and IL-15 receptor (IL-15R)
6*>L
ud 12.MHC restriction
^5Lk}<utw 13.Affinity-chromatography
w5%i 14.Cyctosprin A, CsA
J@$~q}iG 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
qT(6T P ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
1VM2CgR a 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
]r|oNGD)G 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
y{hy7w' d 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
/ 'qoKof Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
,n8\y9{G ÃâÒßѧרҵ£º
9/(jY$Ar 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
bqAW Ïû»¯ÄÚ¿Æ£º
[MFnS",7c 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
tWIJ,_8l ѪҺ²¡Ñ§×¨Òµ£º
BtC*]WB"_' 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
&2`p#riAS Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
zd=O;T;. (רҵ»ù´¡: ÃâÒßѧ)
1Hr}n6s Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
VX$WL"A 1. ADCC(antibody dependent cell-mediated cytotoxicity)
7pyzPc#_ 2. »·æß¾úËØ(cyclosporin)
cl%+m 3. KIR(killer cell inhibitory receptor)
tR|dnC4U 4. HLDA(human leucocyte differentiation antigen)
Cf2WBX$ 5. Interleukin 18(IL-18)
3T2]V? 6. ÕûºÏËØ(integrin)
Dw%'u'HG 7. Fas/FasL
f82%nT 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
T-en|. 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
r=H?fTY<3E 10. Th1/Th2
$a M5jH< 11. »ùÒòÒßÃç(DNAÒßÃç)
^m |@pp 12. chemokines and chemokine receptor
8:,($a/KF 13. ÃâÒßÄÍÊÜ
KewW8H~tb 14. ¹²´Ì¼¤·Ö×Ó
v'W{+>. 15. ËÀÍö½á¹¹Óò(death domain)
Y[{:?i~9, ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
D'g,<-ahl 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
`q?3ux 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
K-0=#6?y4 £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
hNN>Pd~; £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
p
F-Lz<V £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
5\+*ml £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
v:t;Uk^Y 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
IO\l8G Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
K:,V>DL ÎÊ´ðÌâ(ÿÌâ25·Ö)
\|HEe{nA 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
K10G+'H^ 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
'`>%RZ] 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
]o6ZZK 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£